ps13
Small moleculeexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 27, 2020 (NCT04396873)
Timeline
Indications
Mechanism of action
- Subtilisin/kexin type 9INHIBITOR
PCSK9 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06920628 | Phase 1 | Jun 18, 2025 | National Institute of Mental Health (NIMH) |
| NCT05062083 | Phase 2 | Dec 7, 2021 | National Institute of Mental Health (NIMH), University of Maryland |
| NCT04582916 | Phase 1 | Jul 20, 2021 | National Institute of Mental Health (NIMH) |
| NCT04396873 | Phase 1 | May 27, 2020 | National Institute of Mental Health (NIMH) |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Institute of Mental Health (NIMH) | Government | 4 | 4 | 2 | 2020 |
| University of Maryland | Academic/Hospital | 1 | 0 | 1 | 2021 |
2 organizations
Page 1 / 1